| Ian B. Walters |
Ian B. Walters founded SalvaRx Group Plc in 2007, where he worked as Chief Executive Officer in 2019. Dr. Walters also currently works at Portage Biotech, Inc., as Chairman & Chief Executive Officer from 2022, SalvaRx Ltd., as Chief Executive Officer, Stimunity SAS, as Chairman, Enzo Biochem, Inc., as Independent Director from 2020, and iOX Therapeutics Ltd., as Director from 2015. Dr. Walters also formerly worked at Bristol Myers Squibb Co., as Executive Director-Global Oncology Clinical, Millennium Pharmaceuticals, Inc., as Medical Director, 3Legs Resources Plc, as Director, RIFT biotherapeutics, Inc., as Director, Sorrento Therapeutics, Inc., as SVP-Translational Medicine & Corporate Development, Bristol-Myers Squibb Canada Co., as Member from 2007 to 2014, and Intensity Therapeutics, Inc., as Chief Medical Officer & Vice President from 2014 to 2023. Dr. Walters received his doctorate degree in 1993 from Albert Einstein College of Medicine, Inc. and Masters Business Admin degree in 2003 from The Wharton School of the University of Pennsylvania. |
| Allan Lee Shaw |
Allan Lee Shaw founded Shaw Strategic Capital LLC in 2005, where he worked as Senior Managing Director from 2005 to 2009. Mr. Shaw also currently works at CalciMedica, Inc. (US), as Director from 2021, Edith & Carl Marks Jch of Bensonhurst, as Director, Evecxia, Inc., as Director from 2023, CalciMedica, Inc., as Independent Director, Portage Biotech, Inc., as Chief Financial Officer from 2020, The American Institute of Certified Public Accountants, as Member, New York State Society of Certified Public Accountants, as Member, and Corporate Directors Group, as Member. Mr. Shaw also formerly worked at Viatel, Inc., as Director from 1996 to 2002, VIVUS, Inc., as Independent Director from 2015 to 2019, Alvarez & Marsal LLC, as Managing Director from 2011 to 2015, NewLead Holdings Ltd., as Chief Financial Officer & Executive Director from 2009 to 2011, Celsus Therapeutics Plc, as Director in 2013, Navios Maritime Holdings, Inc., as Director from 2005 to 2010, Akari Therapeutics Plc, as Independent Director from 2013 to 2016, Central New York Biotech Accelerator, as Director from 2009 to 2013, Blue Water Biotech, Inc., as Independent Non-Executive Director from 2020 to 2022, Syndax Pharmaceuticals, Inc., as Chief Financial Officer, Secretary & Treasurer from 2016 to 2017, Serono SA, as Chief Financial Officer from 2002 to 2004, Deloitte & Touche LLP, as Manager, and Merck Serono SA, as Chief Financial Officer. Mr. Shaw received his undergraduate degree in 1986 from State University of New York College at Oswego. |
| Robert Alan Kramer |
Robert Alan Kramer is the founder of SalvaRx Group Plc, which was founded in 2007. He is currently a Director at Phusis Therapeutics, Inc. since 2014, a Director at iOX Therapeutics Ltd. since 2022, and the Chief Scientific Officer at Portage Biotech, Inc. since 2019. Dr. Kramer's former positions include Head-Oncology Discovery Research at Janssen Pharmaceuticals, Inc. and Bristol-Myers Squibb Pharmaceuticals Ltd., and Assistant Professor at Harvard Medical School. He received a doctorate degree from the University of Vermont. |
| Steve Innaimo |
Steve Innaimo is currently the Vice President-Project Management & Operations at Portage Biotech, Inc. Prior to this, he worked as the Senior Director-Oncology Project Management at Bristol Myers Squibb Co. from 1994 to 2017 and as the Executive Director & Head-Project Management at Labcorp Drug Development, Inc. from 2017 to 2018. Innaimo received his undergraduate and graduate degrees from the University of Connecticut. |
| Brian Wiley |
Brian Wiley is the founder of Boston Bioconsulting LLC, which was founded in 2018. He held the title of Principal at the company. Currently, Mr. Wiley is the Chief Business Officer at Portage Biotech, Inc. since 2022 and the Senior VP-Corporate Development & Strategy at Aprea Therapeutics, Inc. since 2023. In his former positions, Mr. Wiley worked as a Senior Director-Oncology Marketing at Celgene Corp., Director-Market Planning at Millennium Pharmaceuticals, Inc., Senior Director-Marketing & Business Development at Gloucester Pharmaceuticals, Inc., and Chief Commercial Officer at NewLink Genetics Corp. from 2016 to 2018. He also worked as a Senior Manager at Aventis Pharmaceuticals, Inc. from 1992 to 2004. Mr. Wiley completed his undergraduate degree at The Pennsylvania State University. |
| Gregory H. Bailey |
Gregory H. Bailey founded Ascent Healthcare Solutions, Inc. in 1995, Portage Biotech, Inc. in 1973, where he is working as Lead Director from 2022, Palantir Group, Inc. in 2002, where he is working as Managing Partner from 2002, and various other companies. Dr. Bailey also founded VirnetX, Inc., V. Fund Investments Ltd., where he worked as Chief Executive Officer, Portage Pharma Ltd., where he is working as Director & Chief Business Officer from 2013, and various other companies. Dr. Bailey also currently works at Portage Pharmaceutical Ltd., as Chairman from 2013, Trojan Technologies USA LLC, as Director, Secure Axcess LLC, as Director, and various other companies. Dr. Bailey also formerly worked at AgeX Therapeutics, Inc., as Chairman from 2018 to 2022, Public Ventures LLC, as Managing Director from 2004 to 2007, Plethora Solutions Holdings Plc, as Independent Non-Executive Director, and various other companies. Dr. Bailey received his doctorate degree from the University of Western Ontario. |
| Joseph P. Ciavarella |
Joseph P. Ciavarella is currently the Chief Accounting Officer at Portage Biotech, Inc. He has held several senior financial positions in the past, including Chief Financial Officer & Senior Vice President at AboveNet, Inc. from 2007 to 2014, Chief Financial Officer & Vice President at PC Group, Inc. from 2004 to 2006, Vice President at Integrated Resources, Inc. from 1983 to 1993, CFO-Alternative Investment Division at PaineWebber, Inc. from 1994 to 1998, Chief Financial Officer at New York Medical, Inc. from 2002 to 2004, Senior Vice President-Finance at Aviation Capital Group LLC from 1998 to 2002, and Chief Financial Officer at Corporate Resource Services, Inc. in 2015. Ciavarella received his undergraduate degree from Hofstra University in 1977. |
| Robert H. Glassman |
Dr. Robert H. Glassman is an Executive Vice President-Search & Evaluation at Enavate Sciences, an Independent Non-Executive Director at Jubilant Therapeutics, Inc., an Independent Director at Tarus Therapeutics, Inc., an Independent Non-Executive Director at Pharvaris NV, a Clinical Assistant Professor at Weill Cornell Medical College and an Independent Director at Portage Biotech, Inc. He is on the Board of Directors at Jubilant Therapeutics, Inc., Umoja Biopharma, Inc., Pharvaris GmbH, Tarus Therapeutics, Inc., Pharvaris NV and Portage Biotech, Inc. Dr. Glassman was previously employed as a Vice Chairman & Managing Director by Credit Suisse Securities (USA) LLC, a Managing Director by Bank of America Merrill Lynch (New York), a Venture Partner by OrbiMed Advisors Private Equity, a Principal by Merrill Lynch & Co., Inc. /Old/, a Consultant by McKinsey & Co., Inc., and a Basic Science Investigator by The Rockefeller University. He received his undergraduate degree from Harvard College and a doctorate degree from Harvard Medical School. |
| Steven Michael Mintz |
Steven Michael Mintz is currently an Independent Director at Portage Biotech, Inc. and the President & Director at St. Germain Capital Corp. He is also a Director at Pool Safe, Inc., Serina Therapeutics, Inc., and Minkids Group. In the past, Mr. Mintz held positions such as President, Chief Executive Officer & Director at Stream Ventures, Inc., Waymar Resources Ltd., and Bridgeport Ventures, Inc. He was also the President, Chief Executive Officer, CFO & Director at Dominion General Investment Corp., Premier Royalty, Inc., and Carlisle Goldfields Ltd. Additionally, he served as an Independent Director at Everton Resources, Inc., ThreeD Capital, Inc., Blue Horizon Global Capital Corp., Rockstar Capital Corp., and First Global Data Ltd. He was the Chief Financial Officer & Director at Pool Safe, Inc. and Pounder Venture Capital Corp. Furthermore, he was the Chief Financial Officer & Secretary at Skyberry Capital Corp. and Lipari Energy, Inc.Mr. Mintz obtained his undergraduate degree from the University of Toronto in 1989. |
| James Mellon |
James Mellon founded Portage Biotech, Inc. in 2013, where he worked as Independent Non-Executive Director from 2013 to 2020, Red Dragon Resources Corp. in 2006, where he worked as Director from 2006 to 2010, Regent Pacific Group Ltd. in 1990, where he is working as Chairman, and various other companies. Mr. Mellon also founded UraMin, Inc. (Canada), Fiera Capital (IOM) Ltd., where he is working as Chairman, Areva Resources Southern Africa, where he worked as Non-Executive Director, and various other companies. Mr. Mellon also currently works at Condor Gold Plc, as Non-Executive Chairman from 2022, Bradda Head Lithium Ltd., as Non-Executive Deputy Chairman, Burnbrae Ltd., as Chairman from 2007, and various other companies. Mr. Mellon also formerly worked at Plethora Solutions Holdings Plc, as Non-Executive Chairman from 2012 to 2016, OKYO Pharma Ltd., as Non-Executive Chairman from 2013 to 2014, Conister Trust Plc, as Chairman in 2008, and various other companies. Mr. Mellon received his graduate degree in 1978 from the University of Oxford. |
| Linda M. Kozick |
Linda M. Kozick is an Independent Director at Portage Biotech, Inc., Rapt Therapeutics, Inc., and Artiva Biotherapeutics, Inc. She is also a Director at Saugatuck Therapeutics, Ltd. Previously, she worked as VP, Head-Immuno Oncology & Oncology Product at Bristol Myers Squibb Co. from 2011 to 2015. Kozick holds an MBA from Chapman University and undergraduate and graduate degrees from SUNY Upstate Medical University. |
| Mark Simon |
Mark Simon was the founder of Torreya Partners LLC. He currently holds the position of Vice Chairman at Alliance for Aging Research, Independent Director at Portage Biotech, Inc., Director at Hutchison Biofilm Medical Solutions, Inc., and Independent Director at Cabaletta Bio, Inc. Previously, he worked as Managing Director & Head-Life Sciences at Citigroup, Inc. from 2002 to 2005, Director at ControlRad, Inc. from 2012 to 2019, Managing Director at Citigroup Asset Management, Independent Non-Executive Director at Sun Pharma Advanced Research Co. Ltd. from 2017 to 2020, Analyst at Robertson Stephens, Inc., and Head-Life Sciences Investment Banking at Citigroup Global Markets India Pvt Ltd. Mr. Simon completed his undergraduate degree at Columbia College (MO) and holds an MBA from Harvard Business School. |
